GLP-1 Weight Loss Drugs Linked to Higher Rates of Nail Detachment, Study Finds
A multinational study presented at EADV Congress 2026 found GLP-1 users were over four times likelier to report nail detachment (39% versus 9%), and weight loss alone did not explain the difference
AI generated image
Users of popular GLP-1 medications such as Ozempic, Wegovy, Mounjaro, Zepbound, Victoza and Trulicity may be at greater risk of a little-discussed side effect: problems with their fingernails. A multinational study has found that people taking these drugs were more than four times as likely to report onycholysis, the medical term for a nail separating from the skin beneath it.
The research was presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026. It is the first controlled study to examine whether GLP-1 therapy and nail health are connected.
Key findings
Among GLP-1 users, 39% reported nail detachment, against just 9% of people who had never taken the drugs. Overall, two-thirds of users (66%) described at least one nail disorder, compared with 53% of the control group. Discoloration also showed a wide gap, affecting 46% of users and 17% of nonusers.
How the study worked
The team looked at 575 people on GLP-1 medications and compared them with 1,329 participants who had type 2 diabetes, obesity or both but had never used the drugs. Volunteers were recruited from France, the United States, Brazil and Mexico.
Why the findings matter
GLP-1 receptor agonists have surged in popularity as tools for managing obesity and type 2 diabetes. They work on a hormone signaling pathway that helps control blood sugar and appetite, which makes them effective for improving metabolic health and supporting weight loss. Researchers are still mapping their effects on other parts of the body, however. Until now, evidence of nail changes during treatment came mostly from isolated reports of suspected adverse reactions, not from comparisons against a control group.
Is weight loss the real culprit?
A natural question is whether the nail changes simply reflect shedding pounds. Fast shifts in body weight can alter nutrient intake and other bodily processes, which in turn may affect the health of nails and hair.
The researchers found that this explanation was not enough. When they restricted the analysis to participants who had lost weight, GLP-1 users still reported significantly more nail problems than those who had not taken the medications, suggesting the drugs themselves may play a role.